Unlock Premium Data: Up to 50% Off InvestingProCLAIM SALE

Why BioCryst Pharmaceuticals Stock Is Falling

Published 11/04/2022, 14:14
Updated 11/04/2022, 15:12
© Reuters.  Why BioCryst Pharmaceuticals Stock Is Falling
BCRX
-

BioCryst Pharmaceuticals Inc (NASDAQ: BCRX) shares are trading lower Monday morning after BofA Securities downgraded the stock and Oppenheimer lowered its price target.

BofA Securities analyst Tazeen Ahmad downgraded BioCryst from a Buy rating to a Neutral rating and announced a $14 price target.

Oppenheimer analyst Justin Kim maintained BioCryst with an Outperform rating and lowered the price target from $20 to $16.

What Happened? On Friday, the company paused enrollment in clinical trials with BCX9930 while it investigates elevated serum creatinine levels seen in some patients.

BioCryst discovers novel, oral, small-molecule medicines that treat rare diseases in which significant unmet medical needs exist and an enzyme plays a key role in the biological pathway of the disease.

The company announced Monday that it will present at the 21st Annual Needham Virtual Healthcare Conference on April 14.

BCRX 52-Week Range: $9.23 - $19.99

The stock was down 7.37% at $10.30 at time of publication, according to data from Benzinga Pro.

Photo: fernandozhiminaicela from Pixabay.

Latest Ratings for BCRX

DateFirmActionFromTo
Dec 2021OppenheimerInitiates Coverage OnOutperform
Nov 2021RBC CapitalMaintainsSector Perform
Nov 2021 Barclays (LON:BARC)MaintainsOverweight
View More Analyst Ratings for BCRX

View the Latest Analyst Ratings

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read at Benzinga

Read the original article on Benzinga

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.